AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 132.66 Increased By ▲ 3.13 (2.42%)
BOP 6.89 Increased By ▲ 0.21 (3.14%)
CNERGY 4.57 Decreased By ▼ -0.06 (-1.3%)
DCL 8.92 Decreased By ▼ -0.02 (-0.22%)
DFML 42.75 Increased By ▲ 1.06 (2.54%)
DGKC 84.00 Increased By ▲ 0.23 (0.27%)
FCCL 32.90 Increased By ▲ 0.13 (0.4%)
FFBL 77.06 Increased By ▲ 1.59 (2.11%)
FFL 12.20 Increased By ▲ 0.73 (6.36%)
HUBC 110.01 Decreased By ▼ -0.54 (-0.49%)
HUMNL 14.40 Decreased By ▼ -0.16 (-1.1%)
KEL 5.53 Increased By ▲ 0.14 (2.6%)
KOSM 8.32 Decreased By ▼ -0.08 (-0.95%)
MLCF 39.67 Decreased By ▼ -0.12 (-0.3%)
NBP 65.50 Increased By ▲ 5.21 (8.64%)
OGDC 198.74 Decreased By ▼ -0.92 (-0.46%)
PAEL 26.00 Decreased By ▼ -0.65 (-2.44%)
PIBTL 7.62 Decreased By ▼ -0.04 (-0.52%)
PPL 159.00 Increased By ▲ 1.08 (0.68%)
PRL 26.24 Decreased By ▼ -0.49 (-1.83%)
PTC 18.35 Decreased By ▼ -0.11 (-0.6%)
SEARL 82.24 Decreased By ▼ -0.20 (-0.24%)
TELE 8.12 Decreased By ▼ -0.19 (-2.29%)
TOMCL 34.40 Decreased By ▼ -0.11 (-0.32%)
TPLP 8.98 Decreased By ▼ -0.08 (-0.88%)
TREET 16.88 Decreased By ▼ -0.59 (-3.38%)
TRG 59.49 Decreased By ▼ -1.83 (-2.98%)
UNITY 27.52 Increased By ▲ 0.09 (0.33%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 10,614 Increased By 206.9 (1.99%)
BR30 31,874 Increased By 160.5 (0.51%)
KSE100 98,972 Increased By 1644 (1.69%)
KSE30 30,784 Increased By 591.7 (1.96%)
World

J&J to deliver up to 400 million Covid vaccines to Africa

  • AVAT can order an additional 180 million doses, for a combined total of up to 400 million doses through 2022.
Published March 29, 2021

WASHINGTON: Up to 400 million doses of Johnson & Johnson's Covid-19 vaccine will be made available to African countries, the US pharmaceutical giant said Monday.

The availability of the single-shot vaccine will be subject to national regulatory approvals in the African Union's 55 member states, with the first shipments expected to arrive in the third quarter of 2021.

"No one is safe until everyone is safe, and we have been committed to equitable, global access to new Covid-19 vaccines," J&J's CEO Alex Gorsky said in a statement.

The company said Janssen Pharmaceutica, a J&J subsidiary, had entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to initially make available up to 220 million doses of its vaccine.

AVAT can order an additional 180 million doses, for a combined total of up to 400 million doses through 2022.

J&J says its vaccine candidate protects against Covid-19 in broad geographical regions -- including those with new variants of the disease.

In a global trial of almost 40,000 people, the J&J vaccine's efficacy against severe disease was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.

But the vaccine has won praise for its single dosage and because it does not need to be frozen -- unlike the shots from Moderna and Pfizer -- making distribution much simpler.

Comments

Comments are closed.